Five years after being diagnosed with colon cancer, I would like to share how my support system continues to play a role in my life after active treatment.

Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among ...

Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; ...

Walking the woods shows me how to release fear, grief, and expectations, trusting that letting go nourishes growth, ...

For men with prostate cancer, radical prostatectomy, or surgical removal of the prostate, isn’t guaranteed to be curative, as ...

The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

Viewing identity through the lens of the seasons underscores the fluid, evolving nature of who we are. Just as the seasons ...

For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.

As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients.

Receiving a “Stand Up to Cancer Day” email gave me the strength to support a friend through her darkest cancer days.

Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope ...